PET/CT Systems Market Size, Share, Growth, and Industry Analysis, By Type (Low-range Slice PET/CT Systems (>20), Middle-range Slice PET/CT Systems (21-64), High-range Slice PET/CT Systems (<64)), By Application (Oncology, Cardiology, Neurology, Others), Regional Insights and Forecast to 2035

PET/CT Systems Market Overview

PET/CT Systems Market size is anticipated to be valued at USD 2488.19 million in 2026, with a projected growth to USD 4291.4 million by 2035 at a CAGR of 6.25%.

The PET/CT Systems market is expanding rapidly due to increasing diagnostic imaging demand across oncology, cardiology, and neurology applications. PET/CT systems combine positron emission tomography and computed tomography technologies to deliver high-resolution anatomical and functional imaging. More than 70% of cancer diagnostic protocols in advanced healthcare facilities now integrate hybrid imaging systems for accurate disease staging and therapy monitoring. Over 60% of tertiary hospitals globally have upgraded imaging departments with digital PET/CT platforms featuring AI-assisted reconstruction and low-dose scanning technologies. Demand for high-slice PET/CT systems has increased by over 45% due to rising preference for faster scanning and improved patient throughput. Healthcare providers are increasingly investing in molecular imaging technologies as chronic disease prevalence continues to rise worldwide. More than 50% of imaging centers are adopting advanced PET/CT systems equipped with time-of-flight technology and silicon photomultiplier detectors, improving lesion detectability and reducing scan duration across clinical environments.

The United States PET/CT Systems market remains one of the most technologically advanced healthcare imaging sectors globally. More than 68% of diagnostic imaging centers in the country utilize hybrid imaging systems for oncology-related procedures. Over 1.9 million new cancer cases annually continue to drive PET/CT scanning volumes across hospitals and outpatient facilities. Approximately 57% of nuclear medicine departments are transitioning toward digital PET/CT platforms equipped with AI-powered workflow optimization tools. More than 72% of academic medical centers utilize high-slice PET/CT systems for neurological and cardiovascular assessments. Mobile PET/CT units have expanded by nearly 30% across rural healthcare networks to improve diagnostic accessibility. Increasing reimbursement support and integration of molecular imaging into precision medicine programs are strengthening adoption rates throughout the U.S. healthcare infrastructure.

Download FREE Sample to learn more about this report.

Key Findings

• Key Market Driver: Over 74% of oncology imaging procedures now rely on hybrid diagnostic imaging, while approximately 63% of hospitals prioritize PET/CT adoption for early-stage tumor detection and therapy monitoring efficiency.
• Major Market Restraint: Nearly 49% of healthcare providers report high installation expenses, while 41% of smaller imaging centers experience operational limitations associated with radioactive tracer handling and maintenance complexity.
• Emerging Trends: Around 58% of newly installed systems incorporate AI-enabled image reconstruction, while 46% of diagnostic facilities prefer digital PET/CT systems with time-of-flight and low-dose scanning capabilities.
• Regional Leadership: North America accounts for nearly 39% of advanced molecular imaging installations, while Asia-Pacific demonstrates over 52% growth in newly established hybrid diagnostic imaging centers.
• Competitive Landscape: Approximately 61% of manufacturers are investing in AI-enhanced imaging software, while 44% focus on compact PET/CT platforms designed for outpatient diagnostic facilities and specialty clinics.
• Market Segmentation: High-range slice PET/CT systems contribute over 48% of advanced clinical imaging demand, while oncology applications represent nearly 71% of overall PET/CT diagnostic procedures globally.
• Recent Development: More than 55% of recent product launches include silicon photomultiplier detector technology, while approximately 47% of imaging innovations focus on reducing scan time and radiation exposure.

PET/CT Systems Market Latest Trends

The PET/CT Systems market is witnessing significant technological transformation driven by advancements in digital imaging, artificial intelligence integration, and precision diagnostics. More than 58% of newly deployed systems now feature digital detector technology that improves sensitivity and image resolution during oncology examinations. Time-of-flight PET imaging adoption has increased by nearly 50% because of its ability to enhance lesion localization and shorten acquisition times. Approximately 46% of healthcare providers are implementing AI-assisted reconstruction software to reduce interpretation errors and accelerate clinical workflows.

Demand for low-dose imaging solutions has risen by over 42% due to growing patient safety concerns regarding radiation exposure. More than 35% of hospitals globally are integrating PET/CT imaging into personalized medicine and targeted therapy assessment programs. Cardiology applications account for nearly 22% of new PET/CT installations as healthcare facilities increasingly adopt hybrid imaging for myocardial viability analysis and inflammatory disease detection.

Portable and mobile PET/CT systems are also gaining momentum, particularly in remote and underserved regions where healthcare accessibility remains limited. Nearly 31% of outpatient imaging centers now prefer compact systems with lower operational footprints. Furthermore, over 40% of manufacturers are developing systems compatible with advanced radiotracers to improve early disease detection and support precision oncology initiatives across global healthcare networks.

PET/CT Systems Market Dynamics

DRIVER

"Rising Demand for Advanced Oncology Imaging"

The increasing prevalence of cancer worldwide is one of the primary growth drivers for the PET/CT Systems market. More than 70% of oncology specialists rely on PET/CT imaging for accurate tumor staging, treatment planning, and recurrence monitoring. Hybrid imaging systems provide superior metabolic and anatomical visualization compared to standalone diagnostic modalities, improving disease characterization and therapy response assessment. Approximately 65% of cancer treatment facilities globally have integrated PET/CT systems into routine clinical protocols due to their ability to identify malignancies at earlier stages.

The growing burden of lung cancer, breast cancer, lymphoma, colorectal cancer, and prostate cancer has significantly accelerated imaging procedure volumes. Over 55% of radiation oncology departments utilize PET/CT imaging for radiation therapy planning because of its precision in target delineation. Furthermore, nearly 48% of healthcare systems are expanding molecular imaging departments to support precision medicine initiatives and personalized cancer therapies.

Technological innovations such as digital detectors, AI-powered image analysis, and time-of-flight reconstruction continue improving scan quality and patient throughput. More than 52% of newly installed systems include advanced software platforms capable of automated lesion segmentation and image optimization. These developments are encouraging hospitals, diagnostic centers, and research institutions to invest in next-generation PET/CT systems, fueling strong market expansion across developed and emerging healthcare economies.

RESTRAINTS

"High Installation and Operational Complexity"

The PET/CT Systems market faces substantial restraints associated with high acquisition, installation, and operational complexity. Nearly 49% of small and mid-sized healthcare facilities identify infrastructure investment as a major barrier to adoption. PET/CT systems require specialized radiation shielding, dedicated imaging suites, and advanced cooling systems, increasing installation complexity across healthcare environments.

Operational expenses also remain significant due to maintenance requirements and radiotracer management procedures. Approximately 44% of imaging facilities report challenges related to radioactive isotope availability and handling logistics. PET imaging depends heavily on short half-life tracers such as fluorodeoxyglucose, which require nearby cyclotron facilities or efficient transportation networks. In developing regions, more than 38% of hospitals experience delays in radiotracer supply, limiting imaging capacity and diagnostic efficiency.

Workforce limitations further impact market expansion. Nearly 36% of healthcare institutions report shortages of trained nuclear medicine technologists and radiologists skilled in PET/CT interpretation. Regulatory compliance associated with radiation safety standards also increases operational burdens for imaging providers. Additionally, maintenance downtime affects approximately 27% of facilities annually, reducing patient throughput and operational efficiency. These factors continue restricting wider PET/CT adoption, especially in low-resource healthcare systems and rural medical centers.

OPPORTUNITY

"Expansion of Precision Medicine and AI Integration"

The rapid expansion of precision medicine initiatives presents significant opportunities for the PET/CT Systems market. More than 60% of oncology research programs now incorporate molecular imaging for targeted therapy evaluation and biomarker analysis. PET/CT systems are increasingly utilized to monitor metabolic responses during immunotherapy and personalized cancer treatment protocols.

Artificial intelligence integration is creating additional growth opportunities across imaging workflows. Approximately 54% of healthcare providers are evaluating AI-powered imaging software capable of automated image reconstruction, lesion detection, and workflow optimization. AI-assisted PET/CT systems improve diagnostic consistency and reduce interpretation times by nearly 35%, enhancing operational productivity within imaging centers.

The growing development of novel radiopharmaceuticals is also expanding application areas beyond oncology. Nearly 28% of ongoing clinical imaging research focuses on neurological disorders such as Alzheimer’s disease and Parkinson’s disease. Cardiology applications are increasing as PET/CT imaging demonstrates enhanced capabilities in myocardial perfusion assessment and inflammatory disease detection.

Emerging economies present additional opportunities due to healthcare infrastructure modernization and rising diagnostic awareness. More than 47% of newly established specialty diagnostic centers in Asia-Pacific are investing in advanced molecular imaging technologies. Mobile PET/CT units and compact imaging systems are also improving accessibility in underserved healthcare regions, creating substantial growth potential for manufacturers and service providers.

CHALLENGE

"Radiation Exposure and Regulatory Compliance Issues"

Radiation exposure concerns and stringent regulatory requirements remain major challenges for the PET/CT Systems market. Approximately 43% of patients express concerns regarding cumulative radiation exposure from repeated hybrid imaging procedures. Healthcare providers are increasingly pressured to minimize radiation doses while maintaining diagnostic accuracy and image quality.

Regulatory frameworks governing radioactive isotope handling, imaging equipment installation, and nuclear medicine operations continue becoming more stringent across multiple countries. Nearly 39% of imaging facilities report delays associated with licensing approvals and compliance audits. Maintaining radiation safety protocols requires continuous staff training, specialized infrastructure, and monitoring systems, increasing operational responsibilities for healthcare institutions.

Environmental concerns related to radioactive waste disposal also present ongoing challenges. More than 31% of diagnostic centers face strict waste management procedures associated with radiopharmaceutical usage. Additionally, cybersecurity risks linked to AI-enabled imaging software and cloud-connected diagnostic platforms are emerging concerns within digitally integrated healthcare systems. These operational, regulatory, and safety challenges continue influencing adoption decisions and market scalability across several regions.

PET/CT Systems Market Segmentation

The PET/CT Systems market is segmented by type and application based on imaging performance, detector technology, and clinical usage patterns. By type, the market includes low-range slice PET/CT systems, middle-range slice PET/CT systems, and high-range slice PET/CT systems, each serving different diagnostic workloads and healthcare facility requirements. High-range systems are increasingly preferred in oncology centers because of improved scan speed and image resolution. By application, oncology remains the dominant segment due to rising cancer incidence globally, while cardiology and neurology applications continue expanding with advancements in molecular imaging technologies and AI-assisted diagnostics.

Download FREE Sample to learn more about this report.

BY TYPE

Low-range Slice PET/CT Systems (>20): Low-range slice PET/CT systems are widely utilized in community hospitals, regional diagnostic centers, and healthcare facilities with moderate imaging workloads. Nearly 34% of smaller imaging facilities continue using low-range systems due to their lower infrastructure requirements and manageable operational complexity. These systems are commonly preferred for routine oncology screening, infection imaging, and general diagnostic evaluations. Approximately 41% of emerging healthcare facilities in developing economies rely on low-range PET/CT systems to improve diagnostic accessibility while controlling capital expenditure. Scan duration in low-range systems is generally higher compared to advanced systems, yet over 46% of outpatient imaging providers consider them sufficient for standard imaging protocols. Advancements in detector sensitivity and reconstruction algorithms have improved image quality by nearly 29% in recently upgraded low-range models. Additionally, more than 32% of refurbished PET/CT installations globally belong to this segment because healthcare providers seek affordable hybrid imaging solutions. The adoption of compact and energy-efficient low-range systems is also increasing in rural healthcare networks where infrastructure limitations restrict installation of high-performance imaging platforms.

Middle-range Slice PET/CT Systems (21-64): Middle-range slice PET/CT systems represent a balanced imaging solution combining improved scan performance with moderate operational costs. Approximately 43% of multispecialty hospitals and urban diagnostic centers prefer middle-range systems because they support a broad spectrum of oncology, cardiology, and neurological applications. These systems offer enhanced spatial resolution and faster acquisition times compared to low-range configurations, improving patient throughput by nearly 37%. Over 48% of healthcare facilities upgrading from conventional imaging technologies choose middle-range PET/CT systems because of their versatility and compatibility with AI-assisted reconstruction software. The integration of time-of-flight imaging technology has improved lesion detectability by approximately 33% within this segment. Middle-range systems are increasingly utilized for therapy response monitoring and precision medicine applications due to their advanced imaging capabilities. Nearly 39% of academic research institutions also deploy middle-range PET/CT platforms for clinical trials involving molecular imaging biomarkers. Demand for these systems continues expanding across Asia-Pacific and Latin America as healthcare infrastructure modernization accelerates and diagnostic imaging awareness improves.

High-range Slice PET/CT Systems (<64): High-range slice PET/CT systems dominate advanced diagnostic imaging environments because of their superior image quality, high-speed acquisition, and advanced detector technologies. More than 48% of tertiary care hospitals and specialized oncology centers utilize high-range systems for complex clinical evaluations. These systems significantly reduce scan duration, with patient throughput improvements exceeding 44% compared to conventional configurations. Approximately 57% of newly installed high-end PET/CT systems include digital detector technology and silicon photomultiplier integration for enhanced sensitivity and lower radiation exposure. High-range systems are extensively used in oncology applications, accounting for nearly 71% of advanced cancer imaging procedures globally. Neurological and cardiovascular imaging applications are also expanding rapidly within this segment due to improved functional imaging capabilities. More than 46% of healthcare providers implementing precision oncology programs prioritize high-range PET/CT systems because of their superior quantitative imaging performance. AI-powered workflow optimization and automated image reconstruction features are integrated into nearly 52% of premium systems, supporting faster interpretation and improved diagnostic confidence. These systems continue gaining adoption across developed healthcare markets where advanced molecular imaging infrastructure remains a clinical priority.

BY APPLICATION

Oncology: Oncology remains the dominant application segment in the PET/CT Systems market due to the increasing use of molecular imaging for cancer detection, staging, therapy planning, and recurrence monitoring. More than 71% of PET/CT imaging procedures globally are associated with oncology diagnostics. PET/CT systems are highly utilized for identifying metabolic activity in tumors, especially in lung cancer, lymphoma, colorectal cancer, breast cancer, and prostate cancer cases. Approximately 67% of radiation oncology centers rely on PET/CT imaging for treatment planning because of its ability to improve target localization accuracy. More than 58% of hospitals worldwide utilize hybrid imaging systems for assessing chemotherapy response and disease progression. AI-assisted PET/CT oncology imaging has improved lesion detection efficiency by nearly 39%, while scan interpretation time has decreased by approximately 31%. Advanced tracers used in oncology applications have increased by over 42% in diagnostic imaging workflows. Nearly 49% of newly installed high-range PET/CT systems are specifically configured for oncology imaging protocols. Growing cancer screening initiatives and rising preference for precision medicine continue strengthening oncology-based PET/CT demand across hospitals, cancer research institutes, and specialty diagnostic facilities worldwide.

Cardiology: Cardiology applications are expanding steadily in the PET/CT Systems market due to increasing demand for advanced cardiovascular disease diagnosis and myocardial viability assessment. More than 24% of hybrid imaging procedures in tertiary care facilities are now related to cardiac evaluations. PET/CT imaging provides superior visualization of myocardial perfusion, inflammatory disorders, and coronary artery disease compared to standalone imaging technologies. Approximately 44% of cardiac specialty centers utilize PET/CT systems for evaluating ischemic heart disease and assessing myocardial blood flow abnormalities. The adoption of PET/CT in inflammatory cardiac disease imaging has increased by nearly 36% because of improved sensitivity and functional assessment capabilities. More than 41% of cardiologists prefer hybrid imaging systems for identifying early-stage vascular inflammation and cardiac sarcoidosis. Advanced AI-based image processing software integrated into PET/CT systems has improved diagnostic workflow efficiency by approximately 29% within cardiovascular imaging departments. Additionally, over 33% of newly upgraded imaging centers include dedicated cardiology imaging protocols within PET/CT systems to support non-invasive diagnostic procedures. Increasing prevalence of obesity, diabetes, and hypertension is also contributing to higher cardiovascular imaging demand across hospitals and outpatient diagnostic facilities.

Neurology: Neurology represents a rapidly growing application area within the PET/CT Systems market due to increasing neurological disorder prevalence and demand for functional brain imaging. More than 19% of advanced molecular imaging procedures globally are associated with neurological evaluations. PET/CT systems are extensively used for diagnosing Alzheimer’s disease, Parkinson’s disease, epilepsy, dementia, and brain tumors. Approximately 46% of neurological research institutes utilize PET/CT imaging to analyze brain metabolism and monitor neurodegenerative disease progression. Hybrid imaging systems improve early-stage neurological disorder detection accuracy by nearly 38% compared to conventional imaging techniques. AI-integrated PET/CT neurological imaging platforms have reduced interpretation variability by approximately 27%, supporting more consistent diagnostic outcomes. Over 35% of specialty neurology centers utilize advanced tracers designed specifically for amyloid plaque and dopamine transporter imaging. Functional brain imaging procedures have increased by more than 32% due to growing awareness regarding cognitive disorders among aging populations. Academic medical centers and neuroscience research organizations are increasingly adopting high-range PET/CT systems with enhanced detector sensitivity for detailed neurological analysis. The expansion of precision neurology and biomarker-driven diagnostics continues accelerating demand for advanced PET/CT imaging technologies globally.

Others: The others segment in the PET/CT Systems market includes applications related to infectious diseases, inflammatory disorders, orthopedic assessments, and emerging clinical research areas. More than 14% of PET/CT imaging procedures are associated with non-oncology and non-cardiology applications. PET/CT systems are increasingly used for detecting inflammatory conditions, autoimmune disorders, and musculoskeletal infections due to their ability to visualize metabolic activity with high precision. Approximately 37% of advanced research hospitals utilize hybrid imaging systems for infectious disease tracking and therapy response monitoring. PET/CT imaging usage in orthopedic applications has increased by nearly 28% because of rising demand for bone infection and implant-related complication analysis. Over 31% of pharmaceutical clinical trials involving molecular imaging biomarkers incorporate PET/CT systems for evaluating treatment efficacy and biological activity. Specialized radiotracers designed for inflammatory imaging applications have expanded by approximately 34% across research and diagnostic institutions. Additionally, veterinary imaging centers are increasingly adopting compact PET/CT systems, contributing to broader application diversity. Hybrid imaging technologies continue evolving across multidisciplinary clinical environments, creating new opportunities for PET/CT utilization beyond traditional diagnostic pathways.

PET/CT Systems Market Regional Outlook

Download FREE Sample to learn more about this report.

North America

North America continues to dominate the PET/CT Systems market due to advanced healthcare infrastructure, high diagnostic imaging adoption, and increasing cancer prevalence. More than 39% of global PET/CT system installations are concentrated across North American healthcare facilities. Approximately 74% of tertiary hospitals in the region utilize hybrid molecular imaging systems for oncology diagnostics and treatment monitoring. Digital PET/CT adoption has exceeded 57% across major imaging centers because of rising demand for improved image quality and faster scan performance. More than 61% of academic medical institutions integrate PET/CT systems into precision medicine and radiopharmaceutical research programs. Cardiology imaging applications account for nearly 23% of PET/CT usage in advanced diagnostic networks. AI-assisted image reconstruction software implementation has increased by approximately 42% among hospitals and outpatient imaging facilities. Additionally, over 48% of newly installed systems in North America include silicon photomultiplier detector technology for enhanced sensitivity and lower radiation exposure. Mobile PET/CT units have also expanded significantly to improve healthcare accessibility across remote and underserved regions.

Europe

Europe represents a technologically mature PET/CT Systems market driven by expanding oncology screening programs, increasing neurological imaging demand, and healthcare modernization initiatives. More than 33% of diagnostic imaging departments across Europe have upgraded to advanced hybrid imaging systems featuring digital detector technologies. Approximately 52% of cancer care centers utilize PET/CT imaging for radiation therapy planning and metabolic tumor analysis. Neurological imaging procedures involving PET/CT systems have increased by nearly 31% due to rising prevalence of neurodegenerative disorders among aging populations. More than 45% of university hospitals and clinical research organizations in the region integrate PET/CT systems into biomarker and radiopharmaceutical studies. Time-of-flight imaging adoption has expanded by approximately 38% because of increasing preference for higher image clarity and reduced scan duration. Over 29% of imaging facilities are investing in AI-based workflow automation technologies to improve operational productivity and diagnostic consistency. Demand for low-dose imaging solutions has also increased substantially as healthcare providers prioritize patient safety and radiation exposure reduction across diagnostic procedures.

Asia-Pacific

Asia-Pacific is emerging as the fastest-expanding PET/CT Systems market due to rapid healthcare infrastructure development, rising chronic disease prevalence, and increasing diagnostic awareness. More than 52% of newly established molecular imaging centers globally are located within Asia-Pacific healthcare markets. Approximately 47% of tertiary hospitals in urban regions are investing in hybrid imaging technologies to improve oncology and neurology diagnostics. Cancer-related imaging procedures account for nearly 69% of PET/CT system utilization across major healthcare institutions in the region. The installation of high-range slice PET/CT systems has increased by over 41% because of growing demand for high-throughput diagnostic imaging. More than 36% of imaging facilities are adopting AI-integrated imaging software to enhance clinical efficiency and lesion detection capabilities. Mobile and compact PET/CT systems are increasingly deployed in regional healthcare networks to improve diagnostic accessibility. Additionally, over 44% of healthcare modernization projects include investments in advanced nuclear medicine infrastructure. Increasing healthcare expenditure, expanding private diagnostic networks, and rising awareness regarding early disease detection continue accelerating PET/CT market penetration throughout Asia-Pacific.

Middle East & Africa

The Middle East & Africa PET/CT Systems market is expanding steadily due to increasing investments in advanced healthcare infrastructure and rising awareness regarding early disease diagnosis. Approximately 28% of newly established specialty hospitals across the region are integrating molecular imaging departments equipped with hybrid PET/CT systems. Oncology imaging remains the leading application segment, accounting for nearly 66% of PET/CT procedures in major urban healthcare centers. More than 34% of imaging facilities are upgrading from conventional nuclear medicine systems to digital PET/CT platforms for enhanced diagnostic precision. The adoption of high-slice PET/CT systems has increased by approximately 26% due to growing preference for faster scan times and improved patient throughput. Government-led healthcare modernization programs are contributing significantly to infrastructure development, particularly in tertiary and research hospitals. Nearly 31% of private diagnostic providers are investing in AI-assisted imaging software to improve workflow efficiency and diagnostic consistency. Additionally, mobile PET/CT imaging units are gaining traction in underserved areas to support broader healthcare accessibility and chronic disease management initiatives.

List of Key PET/CT Systems Market Companies

• Siemens AG
• Hitachi, Ltd.
• Koninklijke Philips N.V.
• Canon, Inc.
• General Electric Company
• MinFound Medical Systems Co., Ltd.
• Neusoft Corporation

Top Companies with Highest Market Share

• Siemens AG: Siemens AG accounts for approximately 24% of advanced PET/CT system installations globally due to its strong portfolio of digital imaging technologies, AI-assisted diagnostic platforms, and high adoption across oncology and research imaging centers. More than 58% of its recently deployed systems feature advanced detector technologies and automated workflow optimization tools.
• General Electric Company: General Electric Company contributes nearly 21% of global PET/CT imaging deployments, supported by extensive adoption in multispecialty hospitals and precision imaging facilities. Approximately 49% of its hybrid imaging systems integrate low-dose imaging technology and high-speed reconstruction capabilities, improving clinical productivity and patient throughput efficiency.

Investment Analysis and Opportunities

The PET/CT Systems market is attracting strong investment activity due to rising demand for precision diagnostics, molecular imaging advancements, and AI-enabled healthcare technologies. More than 54% of healthcare infrastructure investment projects globally now include nuclear medicine and hybrid imaging modernization initiatives. Approximately 47% of imaging equipment manufacturers are increasing investments in digital PET/CT platforms with advanced detector technologies and automated reconstruction software.

Private diagnostic chains and specialty oncology centers are also expanding capital allocation toward high-range PET/CT systems to improve patient throughput and diagnostic accuracy. More than 42% of healthcare providers prioritize investments in low-dose imaging technologies because of growing concerns regarding radiation exposure. Emerging economies present substantial growth opportunities, with nearly 39% of new hospital development projects integrating advanced molecular imaging departments. AI-assisted imaging software investment has increased by approximately 36% as healthcare facilities focus on improving workflow efficiency and reducing interpretation variability. Furthermore, over 33% of radiopharmaceutical research initiatives involve PET/CT-compatible tracer development, creating additional opportunities for equipment manufacturers and imaging technology providers.

New Products Development

The PET/CT Systems market is witnessing continuous product innovation focused on improving image quality, reducing scan duration, and enhancing operational efficiency. More than 57% of newly launched PET/CT systems incorporate digital detector technologies capable of increasing sensitivity and improving lesion detectability. AI-integrated imaging platforms are included in approximately 49% of recent product introductions to support automated image reconstruction and workflow optimization.

Manufacturers are increasingly developin